Skip to main content
Home
Latest news
Browse topics
Lupus Rheumatoid arthritis Spondyloarthropathies COVID-19 Browse all topics
In focus
Bimekizumab: Dual IL-17A/IL-17F inhibition in SpA Anifrolumab for the treatment of SLE JAK inhibitor safety: Weighing up the data and understanding the risks Rituximab and rheumatology practice in the COVID-19 era Safety snapshot: Upadacitinib in patients with PsA Repurposing rheumatology drugs for COVID-19 Telemedicine in rheumatology: COVID-19 and beyond Managing PsA in resource-limited settings
Conferences
ACR Convergence 2022 EULAR 2022 Congress
About us
Medicine Matters Rheumatology
EXTENDED SEARCH

Medicine Matters rheumatology

Paul Emery declares the following relationships:

Grants/ research support: Paul Emery has received research grants paid to his employer from AbbVie, BMS, Pfizer, MSD and Roche.

Consulting or advisory role: Paul Emery has undertaken clinical trials and provided expert advice to Pfizer, MSD ,Abbvie, BMS, UCB, Roche, Novartis, Samsung, Sandoz and Lilly. He has also received consultant fees from BMS, AbbVie, Pfizer, MSD, Novartis, Roche and UCB.


John Fitton declares the following relationships:

Participation in a company sponsored speaker bureau: John Fitton has received speaker fees from Pfizer.